China & GSK plc
4 shared events · Importance 4 · Last updated Jun 11, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
NewsDesk Dashboard
Tech
China: Regulators in China are considering bepirovirsen, which could expand the drug's market reach and provide a new treatment option for patients in the country.
GSK plc: As a developer and funder of bepirovirsen, GSK plc stands to benefit significantly from the drug's potential approval and market success, enhancing its reputation and financial outlook in the pharmaceutical industry.
May 28, 2026 · 8 articles
Business
China: China>>>'s stock market, represented by the Shanghai Stock Exchange Composite Index>>>, shed points.
GSK plc: GSK plc>>> agreed to acquire GSK plc>>> for $10.6 billion, marking its largest deal in years and expanding its presence in cancer drug development.
May 20, 2026 · 66 articles
Business
China: China is referenced as another emerging market where Haleon has recently invested, highlighting the company's broader strategy for growth in such regions.
GSK plc: GSK plc is mentioned as the former parent company from which Haleon was spun off in 2022, providing historical context to Haleon's current operations.
Jun 08, 2026 · 13 articles
NEWSDESK
Explore this relationship live
Track how China and GSK plc interact across events, view sentiment trends, and discover connected entities.
Open Dashboard